We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Etomidate Versus Ketamine for Emergency Endotracheal Intubation: a Prospective Randomized Clinical Trial (EvK)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02643381
Recruitment Status : Completed
First Posted : December 31, 2015
Results First Posted : December 15, 2021
Last Update Posted : December 15, 2021
Sponsor:
Information provided by (Responsible Party):
Gerald Matchett, University of Texas Southwestern Medical Center

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Patients who are having problems breathing sometimes require placement of a breathing tube in their mouth and windpipe. The purpose of this breathing tube is to save the patient's life. It is common to give the patient a medication to sedate him or her before the breathing tube is placed. For patients who are gravely ill two medications are commonly used: etomidate or ketamine. Both medications have risks and benefits. Researchers at UT-Southwestern Medical Center and Parkland Memorial Hospital would like to do a study to figure out which one is better for our patients.

Condition or disease Intervention/treatment Phase
Cardiopulmonary Arrest Respiratory Arrest Drug: Etomidate Drug: Ketamine Procedure: Emergency Endotracheal Intubation Device: Mechanical Ventilation Phase 4

Detailed Description:

Critically ill individuals who require emergency endotracheal intubation (placement of a breathing tube in the patient's mouth) usually require sedation or anesthesia to make this process tolerable. There are several medication choices for anesthesia, including medications like etomidate, ketamine and propofol. Of these, etomidate and ketamine are frequently used for critically ill patients because they have minimal effects on the patient's vital signs (blood pressure and heart rate). Both etomidate and ketamine are standard-of-care medications, locally and nationally, and both are frequently used to sedate a patient for this procedure. Both etomidate and ketamine have potential side effects. One of the potential side effects of etomidate is suppression of adrenal gland function. It is not known if this affects patients' outcomes in significant ways. One of the potential side effects of ketamine is a slight increase in patients' heart rates. It is not known if this affects patients' outcomes in significant ways.

The EvK Trial will be conducted at Parkland Memorial Hospital by investigators in the Departments of Anesthesiology, Emergency Medicine, Medicine / Critical Care Medicine, Surgery, and Pharmacy. The study will randomize critically ill patients who require emergency endotracheal intubation to one of two groups: Etomidate or Ketamine. We will observe the patients' outcomes. The only study intervention involves randomizing individual patients to one medication or the other. All study follow-up beyond that point is done by review of medical records.

Because of the nature of this study - an emergency procedure on a critically ill patient - the study will require institutional review board permission not to obtain written informed consent from the patient prior to randomization of study drug for administration for endotracheal tube placement. Prior to enrollment of patients the study team will carry out a comprehensive Community Consultation Plan, which is designed to inform the community about the research study. This is in accordance with rules set forth by the U.S. Food and Drug Administration (FDA 21 CFR 50.24).

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 801 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Etomidate Versus Ketamine for Emergency Endotracheal Intubation: a Prospective Randomized Clinical Trial
Actual Study Start Date : June 6, 2016
Actual Primary Completion Date : December 1, 2020
Actual Study Completion Date : December 1, 2020

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Etomidate
Patients randomized to this group will receive etomidate immediately prior to emergency endotracheal intubation.
 Drug: Etomidate
Patients randomized to this group will receive etomidate immediately prior to emergency endotracheal intubation.

Procedure: Emergency Endotracheal Intubation
Patients enrolled in the study will be endotracheally intubated. (A breathing tube will be placed into the patient's mouth and trachea). This procedure is being done as part of standard emergency care. Standard endotracheal tubes will be used. Our hospital uses primarily Mallinckrodt (TM) brand endotracheal tubes.

Device: Mechanical Ventilation
Patients enrolled in the study will be mechanically ventilated, using a standard ventilator used in our hospital. The mechanical ventilator is attached to the patient's endotracheal tube and helps sustain the patient's life. Our hospital uses several brands of mechanical ventilators.
Experimental: Ketamine
Patients randomized to this group will receive ketamine immediately prior to emergency endotracheal intubation.
 Drug: Ketamine
Patients randomized to this group will receive ketamine immediately prior to emergency endotracheal intubation.

Procedure: Emergency Endotracheal Intubation
Patients enrolled in the study will be endotracheally intubated. (A breathing tube will be placed into the patient's mouth and trachea). This procedure is being done as part of standard emergency care. Standard endotracheal tubes will be used. Our hospital uses primarily Mallinckrodt (TM) brand endotracheal tubes.

Device: Mechanical Ventilation
Patients enrolled in the study will be mechanically ventilated, using a standard ventilator used in our hospital. The mechanical ventilator is attached to the patient's endotracheal tube and helps sustain the patient's life. Our hospital uses several brands of mechanical ventilators.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Survival at Day 7 [ Time Frame: Day 7 ]
    Survival is defined as the number of participants survived at day 7 following emergency endotracheal intubation


Secondary Outcome Measures :
  1. Survival at Day 28 [ Time Frame: Day 28 ]
    Survival is defined as the number of participants survived at day 28 following emergency endotracheal intubation

  2. Sequential Organ Failure Assessment (SOFA) Scores [ Time Frame: Day 1, Day 2, Day 3, Day 4 ]
    Sequential Organ Failure Assessment (SOFA) is a scoring system that assesses the performance of several organ systems. Possible scores range from 0 to 24. Higher score indicates higher degree of organ dysfunction

  3. Duration of Mechanical Ventilation [ Time Frame: From time of documented insertion until the time of documented removal, assessed up to 28 days ]
    Duration (in days) from insertion to removal of mechanical ventilation

  4. Duration of Catecholamine Therapy [ Time Frame: From time of documented start of therapy until the time of documented end of therapy, assessed up to 28 days ]
    Time (in days) from start to end of catecholamine therapy

  5. Length of Stay in ICU [ Time Frame: Assessed up to 28 days ]
    Length (in days) of ICU stay

  6. Number of Participants With New Diagnosis of Adrenal Insufficiency [ Time Frame: Day 28 ]
    New diagnosis of adrenal insufficiency will be assessed by the the primary treating medical or surgical team via chart review

  7. Number of Attempts Necessary to Intubate [ Time Frame: Immediate (Day 1) ]
    This referrers to the number of documented intubation attempts necessary to intubate the patient.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult patient (male or female) requiring emergency endotracheal intubation.

Exclusion Criteria:

  • Children (<18 years old).
  • Women who are known to be pregnant.
  • Any patient who has been previously randomized in the EvK Trial.
  • Patients who require endotracheal intubation without sedative medication. For example, patients in full cardiac arrest.
  • Patients with a known allergy to ketamine or etomidate.
  • Any individual wearing a MedAlert bracelet indicating that he/she has formally opted out of the EvK Trial.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02643381


Locations
Layout table for location information
United States, Texas
Parkland Hospital
Dallas, Texas, United States, 75235
Sponsors and Collaborators
University of Texas Southwestern Medical Center
Investigators
Layout table for investigator information
Principal Investigator: Gerald Matchett, MD University of Texas
  Study Documents (Full-Text)

Documents provided by Gerald Matchett, University of Texas Southwestern Medical Center:
Study Protocol and Statistical Analysis Plan  [PDF] December 30, 2016

More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications of Results:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Gerald Matchett, Associate Professor of Medicine, University of Texas Southwestern Medical Center
ClinicalTrials.gov Identifier: NCT02643381    
Other Study ID Numbers: 022015-023
First Posted: December 31, 2015    Key Record Dates
Results First Posted: December 15, 2021
Last Update Posted: December 15, 2021
Last Verified: November 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Aggregate anonymous data will be published in accord with our IRB approval.
Keywords provided by Gerald Matchett, University of Texas Southwestern Medical Center:
etomidate
ketamine
endotracheal intubation
anesthesia induction medications
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Arrest
Emergencies
Disease Attributes
Pathologic Processes
Heart Diseases
Cardiovascular Diseases
Ketamine
Etomidate
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
 Physiological Effects of Drugs
Anesthetics, Dissociative
Anesthetics, Intravenous
Anesthetics, General
Anesthetics
Central Nervous System Depressants
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Hypnotics and Sedatives